Granisetron Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR (2024 - 2029) | 6.20 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Granisetron Market Analysis
The Granisetron Market is expected to register a CAGR of 6.20% during the forecast period.
The key factors propelling market growth are the rise in chemotherapy and radiotherapy visits, along with the increasing prevalence of gastroparesis. The rising burden of cancer is expected to propel chemotherapy and radiotherapy visits, which can ultimately cause chemotherapy-induced vomiting, subsequently creating demand for granisetron.
Chemotherapy drugs frequently induce nausea and vomiting. These symptoms can manifest after treatment commences, lasting for 24 to 48 hours. However, for some individuals, the discomfort can persist for as long as seven days post-treatment. Various research studies have demonstrated the importance of granisetron in the treatment of chemotherapy-induced vomiting. For instance, as per the article published in June 2024 in the Lung Cancer journal, researchers showed that prophylactic treatment combining mirtazapine with granisetron and dexamethasone demonstrates promising efficacy and a favorable safety profile for carboplatin (CBDCA)-induced nausea and vomiting in patients with thoracic cancers.
Furthermore, various clinical trials have been conducted worldwide to understand the effectiveness of granisetron in various conditions. For instance, in September 2023, Ain Shams University sponsored a clinical trial to evaluate the efficacy of granisetron versus ondansetron for nausea and vomiting in the pediatric age group. Thus, studies evaluating the efficacies of treating nausea and vomiting are expected to boost the administration of granisetron, which is expected to fuel market growth.
Thus, due to the abovementioned factors, the market studied is expected to grow significantly during the forecast period. However, the adverse effects of granisetron are expected to hinder market growth.
Granisetron Market Trends
The Injection Segment is expected to witness significant growth in the market
Granisetron hydrochloride injection is a serotonin-3 (5-HT3) receptor antagonist indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. The recommended dosage for granisetron hydrochloride injection in adults is 10 mcg/kg, whereas the recommended dose in pediatric patients two to 16 years of age is 10 mcg/kg. When granisetron is used to prevent nausea and vomiting caused by cancer medicines (chemotherapy), it is usually given 30 minutes before the start of chemotherapy. However, when used to prevent and treat nausea and vomiting caused by surgery, it is usually given 30 seconds before anesthesia or right after surgery if nausea and vomiting begin.
An increase in research studies demonstrating the benefit of intravenous granisetron over other routes is expected to drive segment growth over the forecast period. For instance, as per the article published in July 2023 in Scientific Reports, researchers studied the efficacy of intravenous granisetron versus prophylactic ephedrine in preventing hypotension post-general anesthesia induction in elderly patients. The study showed that administering intravenous granisetron to elderly patients during general anesthesia induction decreased the need for prophylactic ephedrine, thereby aiding in the prevention of post-induction hypotension. Hence, owing to such benefits offered by the granisetron injection, its adoption is expected to rise, leading to segment growth over the forecast period.
Thus, owing to the ease of administration and efficiency, the injection segment is expected to drive growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same During the Forecast Period
North America is expected to witness notable growth in the granisetron market owing to the high burden of cancer cases, increase in the prevalence of gastroparesis, and rise in the adoption of granisetron among cancer patients.
The high prevalence of cancer cases necessitates the requirement for chemotherapy and radiotherapy, which is expected to ultimately drive market growth in the country. For instance, as per the American Cancer Society 2024 report, 2 million cancer cases are estimated to be diagnosed in the United States, a considerable increase from 1.9 million in 2023. The high incidence of cancer indicates the increasing patient visits for chemotherapy and radiotherapy, thereby increasing the demand for granisetron for addressing the symptoms and fueling the growth of the market.
Furthermore, the US government approved various formulations of granisetron for treating cancer-induced vomiting. For instance, as per the July 2023 update by the National Cancer Institute, the guideline suggested that when corticosteroids are not suitable, the recommended approach is to administer nabilone or chlorpromazine alongside ondansetron or granisetron to children undergoing highly emetogenic chemotherapy. As per the same source, in the United States, granisetron is approved in various forms, such as injections, extended-release injections, transdermal patches, and oral tablets for initial and repeat prophylaxis in patients undergoing emetogenic chemotherapy, notably those on high-dose cisplatin regimens.
Thus, owing to the availability of granisetron and the increase in benefits offered by granisetron, the market is anticipated to lead to significant growth in the region during the study period.
Granisetron Industry Overview
The granisetron market is semi-consolidated in nature due to the presence of several companies operating globally and regionally. Some of the major players in the market are Kyowo Kirin Co. Ltd, Heron Therapeutics, Fresenius SE & Co. KGaA, Hikma Pharmaceuticals, and Viatris. The key market players are strategically involved in various activities, such as product launches, collaborations, and expansions, in order to improve their product portfolio.
Granisetron Market Leaders
-
Kyowa Kirin Co., Ltd.
-
Heron Therapeutics, Inc.
-
Viatris
-
Hikma Pharmaceuticals PLC
-
Fresenius SE & Co. KGaA
*Disclaimer: Major Players sorted in no particular order
Granisetron Market News
- March 2022: Acino acquired six South African prescription medicines from Aspen Pharmacare Holdings Limited for over EUR 105 million, including the Aspen Granisetron brand.
- January 2022: Cumberland Pharmaceuticals Inc. entered an agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO (granisetron transdermal patch) from Kyowa Kirin Inc., the US affiliate of Japan-based Kyowa Kirin Co. Ltd.
Granisetron Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumption and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rise in Chemotheraphy and Radiotherapy Visits
- 4.2.2 Increasing Incidence of Gastroparesis
-
4.3 Market Restraints
- 4.3.1 Adverse Effects of Granisetron
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Product Type
- 5.1.1 Transdermal System
- 5.1.2 Injection
- 5.1.3 Oral
-
5.2 By Application
- 5.2.1 Chemotherapy
- 5.2.2 Post-operative
-
5.3 By Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Rest of the World
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Kyowa Kirin Co. Ltd
- 6.1.2 Heron Therapeutics Inc.
- 6.1.3 Fresenius SE & Co. KGaA
- 6.1.4 Hikma Pharmaceuticals PLC
- 6.1.5 Cipla Inc.
- 6.1.6 Novartis
- 6.1.7 Viatris
- 6.1.8 Natco Pharma
- 6.1.9 Dr. Reddy's Laboratories Ltd
- 6.1.10 Akorn Operating Company LLC
- 6.1.11 Merck KGaA
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityGranisetron Industry Segmentation
As per the scope of the report, granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its major effect is to reduce the activity of the vagus nerve, the nerve that activates the vomiting center in the medulla oblongata.
The granisetron market is segmented by product type, application, and geography. By product type, the market is segmented into transdermal, injection, and oral. By application, the market is segmented into chemotherapy and post-operative. By geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. The report offers the value (USD) for the above segments.
| By Product Type | Transdermal System | |
| Injection | ||
| Oral | ||
| By Application | Chemotherapy | |
| Post-operative | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| By Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| By Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| By Geography | Rest of the World |
Granisetron Market Research FAQs
What is the current Granisetron Market size?
The Granisetron Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)
Who are the key players in Granisetron Market?
Kyowa Kirin Co., Ltd., Heron Therapeutics, Inc., Viatris, Hikma Pharmaceuticals PLC and Fresenius SE & Co. KGaA are the major companies operating in the Granisetron Market.
Which is the fastest growing region in Granisetron Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Granisetron Market?
In 2024, the North America accounts for the largest market share in Granisetron Market.
What years does this Granisetron Market cover?
The report covers the Granisetron Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Granisetron Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Granisetron Industry Report
Statistics for the 2024 Granisetron market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Granisetron analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
